Crown Laboratories Initiates Tender Offer for Revance Shares
Crown Laboratories, Inc., a recognized leader in the skincare industry, has taken a significant step by launching a cash tender offer aimed at acquiring all outstanding common shares of Revance Therapeutics, Inc. This offer is set at a price of $3.10 per share in cash. With the endorsement of Revance’s Board of Directors, this initiative promises both immediate liquidity and a secure valuation for stockholders.
Revance Board’s Unanimous Support
The support from the Revance Board highlights the favorable conditions surrounding this transaction. They have unanimously stated that the offer and ensuing merger are not only advisable but align closely with the best interests of Revance and its shareholders. The Board undertook a thorough analysis of various strategic options, engaging with several potential partners, to ascertain the viability of this deal.
Financial Benefits of the Cash Offer
The Revance Board considered multiple factors, including the evolving landscape of the aesthetic injectable sector and potential risks tied to Revance’s current debt commitments. After assessing these elements, they concluded that the certainty of the $3.10 cash offer serves in the best interests of shareholders, particularly when faced with the uncertainties related to Revance's independent operational strategy.
Tender Offer Highlights
The tender offer was officially filed with the U.S. Securities and Exchange Commission (SEC), outlining the specifics in a Schedule TO statement. This document presents the terms of the cash offer and is supported by the Revance Board’s recommendations for shareholders to engage with this opportunity.
Future Outlook and Acquisitions
The offer is poised to expire shortly after midnight on January 13, granting shareholders a window to participate unless the terms are extended. Following a successful tender, Crown plans to acquire any remaining shares through a secondary merger, mirroring the offer extended to participants in the tender offer.
About Crown Laboratories
Crown Laboratories stands as a fully integrated skincare company dedicated to enriching the lives of consumers with a diverse array of aesthetic and therapeutic products. Their relentless focus on innovation in skin science has positioned them as a premier player in both Dermatology and Aesthetics. With over a decade on the Inc. 5000 Fastest Growing Privately Held Companies List, Crown continues to expand its reach globally, distributing products in more than 50 countries.
Key Information Updates
This announcement serves as an outline and is not a formal solicitation to purchase shares of Revance. The official solicitation is being conducted through the detailed documents filed with the SEC, which will be provided free of charge to Revance’s stockholders. These documents will detail the tender offer process and the benefits associated with participation.
Frequently Asked Questions
What is the purpose of Crown Laboratories' tender offer?
The tender offer aims to acquire all outstanding common shares of Revance Therapeutics to enhance value for shareholders.
How much is Crown offering for Revance shares?
Crown Laboratories has proposed a cash offer of $3.10 per share for Revance common stock.
Why did Revance's Board support this offer?
The Board believes the offer provides immediate liquidity and certainty of value, which is beneficial under the current market conditions.
What happens if the tender offer is successful?
If successful, Crown will acquire any shares of Revance not tendered in a secondary merger at the same price offered in the tender.
Where can shareholders find more information?
Shareholders can access detailed information and documents related to the tender offer through the SEC's website.
